What is API Holdings? (Start here if you're new)

By Kanishk Devbangia, NISM Series XV Certified Research Analyst (NISM-202300182946)

If you've ever ordered medicines online in India, you've probably used PharmEasy. But the actual company that runs it — the parent entity behind the scenes — is called API Holdings Private Limited.

API Holdings is not listed on the stock exchange. You cannot buy it on NSE or BSE like you buy Infosys or Reliance. It is what is called an unlisted or pre-IPO company — a large private company that operates, earns revenue, and has investors, but has not yet gone public.

The company was incorporated on 31 March 2019 and today is India's largest integrated digital healthcare platform by Gross Merchandise Value (GMV). It operates across medicine delivery, diagnostics, hospital supply, and healthcare software.

The 3-part business model — explained simply

B2B — Bulk Supply (Ascent + Aknamed)

Supplies medicines in bulk to thousands of chemists (Ascent) and hospitals (Aknamed). Focus is on scale, speed, and supply chain. This is the most stable part of the business.

B2C — PharmEasy App Customer Engine

The app you use to order medicines, book lab tests, or consult a doctor online. Still improving — losses are narrowing but not yet profitable on its own.

Diagnostics — Thyrocare

India's largest diagnostic lab network. High margins, positive cash flow. Thyrocare is already listed on NSE separately. This segment funds the rest of the group.

The valuation crash — from $5.6 billion to $710 million

To understand why the current share price of ₹6.05 matters, you need to know the history. This company has had one of the most dramatic valuation stories in Indian startup history.

• 2021 — Peak

PharmEasy raises massive funding. Valued at $5.6 billion (~₹46,000 Cr). Files for IPO. Everyone is excited. The company acquired Thyrocare for ₹4,546 Cr, making it the biggest e-health deal in India. Co-founders become paper billionaires.

• 2021–22 — IPO withdrawn

Market conditions worsen. PharmEasy withdraws its IPO application. Cash burn is extremely high. Losses mount. The company starts restructuring.

• 2023 — Recapitalisation at 90% discount

Ranjan Pai (Manipal Group), Prosus Ventures, Temasek, TPG backed a rights issue that raised ₹3,500 Cr. But the price? The company was valued at only $710 million — a 90% crash from its 2021 peak. Three co-founders step back from operations.

• 2024–2026 — Recovery begins

Cost discipline kicks in. Losses more than halved. Thyrocare keeps growing. And in Q3 FY26, group EBITDA turns positive for the first time. IPO discussions restart. New CEO takes charge.

Major leadership change — the CEO you need to know

In August 2025, API Holdings went through a major leadership transition that most investor blogs have ignored — but it matters. \

Siddharth Shah, the co-founder who built PharmEasy from scratch, stepped down as CEO. He moved to the role of Director and Vice Chairman at API Holdings.

Rahul Guha, who was previously the MD & CEO of Thyrocare (the profitable diagnostics arm), took over as PharmEasy's CEO from August 21, 2025.

Q3 FY26 results — what happened and what it means

The headline of Q3 FY26 is simple: EBITDA turned positive at the group level. This is the first time in the company's history. Let's break down what that actually means and segment by segment.

💡 WHAT IS EBITDA AND WHY DOES IT MATTER?

EBITDA stands for Earnings Before Interest, Tax, Depreciation and Amortisation. Think of it as "how much money the company makes from its actual operations — before paying loans, taxes or accounting costs."

Going EBITDA-positive means the core business is no longer losing money day-to-day. It is the first major milestone on the road to full profitability.

Core group financials — 9 months FY26 vs 9 months FY25

Current share price, IPO plans & reverse merger

Current unlisted share price (April 2026) : ₹6.05

52-week range : ₹5.00 (low) — ₹12.00 (high)

Face value : ₹1.00

Minimum investment : ₹10,000

Lot size : 5,000 shares

Market cap (est.) : ~₹11,071 Cr

IPO status : Not filed

IPO expected 2026–2027

The reverse merger plan — what is it?

This is the most important development for investors right now. Unlisted axis is seriously considering a reverse merger with Thyrocare to get listed on Indian stock exchanges.

WHAT IS A REVERSE MERGER?

Normally, a private company lists on a stock exchange by doing an IPO (filing papers, getting SEBI approval, issuing new shares to the public). A reverse merger is a shortcut — the private company merges with an already-listed public company (Thyrocare). Because Thyrocare is already on NSE, API Holdings becomes listed automatically without going through the long IPO process.

Thyrocare is already listed on NSE and is 71.18% owned by API Holdings. A reverse merger would allow PharmEasy to go public without the full SEBI IPO process — faster and with less regulatory risk. The company discussed this strategy at a board meeting in February 2026.

For unlisted share investors: If the IPO or reverse merger happens, your unlisted shares will convert to listed shares — and you'll be able to trade them on NSE/BSE like normal stocks after a 6-month lock-in period. The IPO price will determine whether you profit or not.

How to buy PharmEasy unlisted shares (legally)

Buying and selling pre-IPO/unlisted shares is 100% legal in India under SEBI regulations. You can do it through registered platforms like Unistedaxis, or similar SEBI-compliant dealers.

The process is:

1. Confirm the price and quantity with a dealer.

2. Transfer funds via bank.

3. Share your demat account details.

4. Shares are transferred to your demat account.

Always use a registered platform and complete full KYC .

Disclaimer:

This content is for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or an offer to buy/sell securities. Unlisted shares are subject to market risks and may not be suitable for all investors. Please consult your financial advisor before making any investment decisions.

Investment in unlisted/pre-IPO securities involves significant risk including illiquidity and capital loss.